The Bad Homburg vor der Höhe-based healthcare group’s fund comes as Europe’s biopharma dealmaking community prepares to descend on Cologne, Germany, forBIO-Europein November.
The new unit will invest in founders, technologies and business models spanning early financing rounds through to growth stage, targeting fields adjacent to Fresenius’ existing strategic platforms of (bio)pharma, medtech and care provision.
“Fresenius Ventures is an integral part of #FutureFresenius and a strategic investment to drive innovation-led growth across Fresenius’ strategic platforms: (Bio)Pharma, MedTech and Care Provision,” Thomas Thestrup, managing director and head of Fresenius Ventures, toldBioXconomy. “The fund invests in areas such as advanced therapies, life science tools and platforms, medical nutrition, MedTech and digitally enabled care delivery. It is designed as an independent, strategically led and financially disciplined corporate venture capital platform with founder-oriented decision-making and clear strategic relevance for Fresenius.”
The fund is intended to work both ways, offering portfolio companies more than capital while giving Fresenius early sight of emerging technology and talent.
“Through Fresenius Ventures, Fresenius gains access to breakthrough technologies, new ideas and entrepreneurial talent. At the same time, portfolio companies can benefit from Fresenius’ medical expertise, industry network, and deep understanding of patient needs. Depending on the company, its stage of development and the strategic fit, this may include access to scientific, medical, manufacturing, commercial, regulatory, digital and operational expertise.”
Acting independently
Despite its corporate backing, the spokesperson told us that the fund is positioned to behave like an independent venture investor.
“While Fresenius Ventures is strategically connected to Fresenius, it operates with the speed, and conviction founders expect from a venture investor. We believe that providing access to our experts and facilitating partnerships across the Fresenius ecosystem can create meaningful value and help innovative companies scale more effectively.”
The launch lands against a European venture landscape that is showing early signs offinding its footingafter a prolonged downturn, though investors remain far from indiscriminate.
Speaking on the current investor climate, Thestrup offered a cautious assessment.
“My personal observation is that theEuropeanventure capital market is gradually stabilizing. At the same time, investors remain highly selective and continue to focus on quality. There is a clear preference for later-stage, de-risked companies and larger financing rounds, often led by well-capitalized investors,” Thestrup said.
That selectivity, Thestrup added, is shaping where capital actually flows. “As a result, capital remains available for companies with experienced leadership teams, a clear product-market fit, strong value propositions and demonstrated commercial traction, particularly in markets with attractive exit opportunities.
“In this environment, companies operating in sectors such as healthcare or artificial intelligence (AI)-enabled technologies continue to attract investor interest. By contrast, businesses with a longer path to profitability or limited differentiation may face a more challenging funding environment.”
BIO-Europe
Over the last 30 years, BIO-Europe has become Europe’s flagship partnering event. Its international reach makes it a one-of-a-kind offering, with attendees from all parts of the biotechnology value chain gathering to efficiently identify, engage and form strategic relationships that drive their businesses successfully forward.
